STOCKS TELEGRAPH

Tag: SY

  • 13 Trending Stocks in Health Information Services Industry

    13 Trending Stocks in Health Information Services Industry

    As investors weighed the stimulus vote of Monday against the emergence of a new ‎coronavirus strain ‎in the UK, US equities ended mixed on Tuesday.
‎

    The Senate approved the measure Monday night after months of negotiations over ‎additional fiscal ‎support. The bill funds the government through September 30 and includes ‎a new stimulus of $900 ‎billion. Also, the package includes $300 in additional federal ‎unemployment benefits and $600 in direct ‎payments. 
‎

    Some of the key players in the Health Information Services sector were:

‎‎

    NantHealth Inc. (NASDAQ:NH) shares were trading up 21.50% at $3.56 at the ‎time of writing on Tuesday.‎

    NantHealth Inc. (NASDAQ:NH) share price went from a low point around $0.92 ‎to briefly over $6.60 in past 52 weeks, though shares have since pulled back to $3.56. NH market cap ‎has remained high, hitting $427.88M at the time of writing, giving it price-to-sales ratio of more than ‎‎5.

    ‎If we look at the recent analyst rating NH, Canaccord Genuity reiterated ‎coverage on NH shares with a Buy rating and a $3.75 price target, which implies ‎room for 0.19% upside momentum this year.

    HMS Holdings Corp. (HMSY) last closed at $36.58, in a 52-week range of $18.19 ‎to $36.75. The company recently reported an agreement with Veritas Capital-backed Gainwell ‎Technologies, whereby Gainwell will acquire HMS. Analysts have a consensus price target of ‎‎$35.09.

    Teladoc Health Inc. (TDOC) stock soar by 3.15% to $206.04. The most recent ‎rating by Evercore ISI, on December 22, 2020, is at an In-line.

    American Well Corporation (NYSE:AMWL) Shares headed rising, higher as much ‎as 5.90%. The most recent rating by Stifel, on December 18, 2020, is at a Hold.

    Veeva Systems Inc. (NYSE:VEEV) rose 5.76% after gaining more than $15.61 on ‎Tuesday. Veeva reported on December 15, 2020, that Integra LifeSciences has selected Veeva Vault ‎CDMS for clinical data management. ‎

    Change Healthcare Inc. (CHNG) last closed at $18.83, in a 52-week range of ‎‎$6.18 to $18.70 following the announcement of successful introduction of its first cloud-based medical ‎tools for radiologists and other specialties along with its roadmap to help healthcare organizations ‎begin their migration of medical imaging to the cloud. Analysts have a consensus price target of ‎‎$20.39.

    GoodRx Holdings Inc. (GDRX) stock soar by 3.49% to $48.32 after announcing ‎recognition from workplace culture site Comparably for its company culture and leadership. The most ‎recent rating by RBC Capital Mkts, on November 19, 2020, is at an Outperform.

    Allscripts Healthcare Solutions Inc. (NASDAQ:MDRX) Shares headed rising, ‎higher as much as 2.15%. The company announced on December 17, 2020, that it is dedicating ‎extensive resources to ensure its clients are prepared to maximize functionality within its solutions to ‎respond to the COVID-19 pandemic. The most recent rating by Argus, on November 11, 2020, is at a ‎Buy.

    HealthEquity Inc. (NASDAQ:HQY) rose 2.27% after gaining more than $1.51 on ‎Tuesday. The company reported on December 8, 2020, that revenue for the third quarter ended ‎October 31, 2020 of $179.4 million grew 14% compared to $157.1 million for the third quarter ended ‎October 31, 2019.

    ‎Cerner Corporation (CERN) last closed at $77.38, in a 52-week range of $53.08 to ‎‎$80.90. The firm on December 16, 2020 revealed an agreement to acquire health division of Kantar. ‎Analysts have a consensus price target of $78.23.

    ‎1Life Healthcare Inc. (ONEM) stock soar by 3.97% to $43.26. The most recent ‎rating by Credit Suisse, on October 30, 2020, is at an Outperform.

    ‎So-Young International Inc. (NASDAQ:SY) Shares headed falling, lower as much ‎as -7.41%. The most recent rating by Deutsche Bank, on April 23, 2020, is at a Buy.

    ‎Schrodinger Inc. (NASDAQ:SDGR) rose 0.85% after gaining more than $0.7 on ‎Tuesday.

  • So-Young International Inc. (Nasdaq: SY) gave upbeat Guidance as its Earnings results meet expectations

    So-Young International Inc. (Nasdaq: SY), China’s biggest and most dynamic social network for the medical aesthetics industry’s customers, practitioners, and service providers, officially released its unaudited financial results for the quarter ended 30 September 2020.

    If we have a look at the financial highlights of Q3, 2020. In accordance with the company’s prior guidance, overall sales were US$53.0 million, an improvement of 18.9 percent from US$45.9. million in the same timeframe in 2019.

    Net sales were US$0.1 million, relative to US$4.8 million in net revenue for the same duration in 2019.

    The net income of non-GAAP2 was US$3.9 million, compared with the net income of non-GAAP of US$6.16 million in the same period of 2019.

    While looking at the Q3 2020 operational highlights, there were 8.7 million monthly smartphones MAUs, a rise of 153.7 percent from 3.4 million in the third quarter of 2019.

    The overall number of consumers buying reservation services was 251,928 and the net volume of transactions enabled by So-website Young’s for medical aesthetic care was US$ 168.7 million.

    On So-Young’s website, the number of paid medical service providers was 4,096, a rise of 26.8 percent from 3,230 in the third quarter of 2019.

    Meanwhile, sales expenses were US$8.1 million, a 1.6 percent rise from US$8.19 million in the Q3 of 2019. In the Q3 of 2020, the cost of sales included share-based compensation costs of US$0.8 million, contrasted with US$0.24 million in the same period of 2019.

    Looking ahead, So-Young estimates gross sales to range between US$61.9 million and US$66.3 million for the fourth quarter of 2020, marking a 17.3 percent to 25.6 percent rise from the same time of 2019. The prediction referred above is based on current economic conditions and represents the Company’s preliminary market and operating conditions and consumer demand predictions, especially in view of the possible continuing impact of COVID-19, the implications of which are difficult to analyze and estimate and are all subject to change.